AVROBIO(AVRO)2025-05-08 20:07Financial Performance - Cash and cash equivalents as of March 31, 2025, were $306.2 million, up from $141.2 million as of December 31, 2024, providing a cash runway into Q4 2028[13] - The net loss for Q1 2025 was $15.9 million, compared to a net loss of $15.2 million in Q1 2024[13] - Total operating expenses for Q1 2025 were $18.3 million, compared to $13.0 million in Q1 2024[16] Research and Development - Research and development expenses for Q1 2025 were $13.0 million, compared to $10.8 million in Q1 2024, reflecting increased costs related to the TX2100 program[13] - Interim analysis from the TX45 Phase 1b Part A trial showed a 17.9% reduction in Pulmonary Capillary Wedge Pressure and over 30% reduction in Pulmonary Vascular Resistance in a subpopulation with more severe disease[7] - Enrollment for Part B of the TX45 Phase 1b trial began in March 2025, with topline results expected in the second half of 2025[6] - Full results from the Phase 1b Part A trial will be presented on May 17, 2025, at the ESC Heart Failure Congress, involving a total of 19 patients[6] - The ongoing APEX Phase 2 trial continues to enroll patients, with topline results expected in 2026[6] Administrative Expenses - General and administrative expenses increased to $5.3 million in Q1 2025 from $2.2 million in Q1 2024, primarily due to higher professional services and stock-based compensation[13] Funding Activities - Tectonic completed a private placement in February 2025, raising approximately $185.0 million in gross proceeds[7]